|
 |
sevelamer hydrochlorideThis page contains recent news articles, when available, and an overview of sevelamer hydrochloride but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Lanthanum carbonate treatment achieved greater reductions in serum phosphorus than did sevelamer hydrochloride in a study of hemodialysis patients with ... Renal and Urology News Tablet Burden Lowest with Lanthanum Carbonate - Nov 1, 2009 CKD patients who used lanthanum carbonate to manage hyperphosphatemia had a lower mean tablet burden than those who took sevelamer hydrochloride or calcium ... Renal and Urology News Genzyme Corporation - SWOT Analysis - New Report Published - Nov 12, 2009 The increase was primarily due to higher sales of Cerezyme ((imiglucerase for injection), Fabrazyme (agalsidase beta), Renagel (sevelamer hydrochloride), ... OfficialWire (press release) Oral Suspension Manages Phosphorus in Hemodialysis Patients - Oct 22, 2009 Sevelamer carbonate powder taken as an oral suspension provides serum phosphorus control in CKD patients comparable to that of sevelamer hydrochloride ... Renal and Urology News Genzyme Reports Third-Quarter Financial Results - Oct 22, 2009 Within this segment, sales of Genzyme's sevelamer therapies, Renvela ® (sevelamer carbonate) and Renagel ® (sevelamer hydrochloride), were $181.7 million in ... Business Wire (press release) Effects of sevelamer and calcium on coronary artery calcification in ... - Mar 13, 2005 Use of calcium containing phosphate binders resulted in more rapid progression of coronary calcification than did use of sevelamer hydrochloride. Nature.com Press Release: Genzyme Reports Strong Fourth-Quarter Revenue … - Jan 11, 2005 Agency has approved the production of Renagel(R) (sevelamer hydrochloride) tablets ... capacity to support the worldwide growth of Renagel, ... Pay-Per-View - PR Newswire - HighBeam Research Genzyme Announces Results of Clinical Trials Investigating Powder... - Jun 18, 2007 Additionally, data showing the equivalence of sevelamer carbonate and sevelamer hydrochloride were presented at the 2007 spring clinical meeting of the ... RedOrbit Press Release: Shire Pharmaceuticals Group PLC - New 6-year data … - Nov 14, 2005 ASN poster, "Influence Of Bile Acids On The Phosphate-Binding Efficacy Of Lanthanum Carbonate And Sevelamer Hydrochloride." 4 Steve Damment, et al. ... Pay-Per-View - PR Newswire UK Disclose - HighBeam Research Genzyme to Participate in FDA Advisory Committee Meeting on the Use... - Oct 12, 2007 Sevelamer hydrochloride provides the added benefit of significant LDL cholesterol ... Sevelamer hydrochloride is used by more than 350000 people worldwide. ... $4.95 - PR Newswire - ECNext Genzyme Files for Approval of Sevelamer Carbonate for Patients on … - Dec 21, 2006 Renvela is being developed as a next generation phosphate binder to replace Renagel(R) (sevelamer hydrochloride), the most-prescribed phosphate binder in ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: Genzyme Files for Approval of Sevelamer Carbonate and ... - Dec 22, 2006 Additionally, data showing the equivalence of sevelamer carbonate and sevelamer hydrochloride were presented at the 2007 ... ... Pay-Per-View - M2 Presswire - HighBeam Research Genzyme to Acquire Bone Care, Adding Complementary Therapy to … - May 4, 2005 The NKF's K/DOQI guidelines recommend sevelamer hydrochloride as a first-line treatment option to reduce phosphorus. Renagel has an established safety ... Wisbusiness.com Genzyme Successfully Completes Study Investigating Sevelamer … - Apr 16, 2007 The drug was well tolerated with a safety profile consistent with the clinical experience of patients on dialysis using Renagel® (sevelamer hydrochloride). ... webwire.com Decreased Hospitalizations and Health Care Costs Associated with … - Nov 16, 2006 The National Kidney Foundation's 2003 K/DOQI guidelines for Bone Metabolism and Disease in Chronic Kidney Disease recommend sevelamer hydrochloride as a ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: Renagel Study in New Dialysis Patients Published in … - Sep 29, 2005 Assistance provider for Renagel(R) (sevelamer hydrochloride). Renagel is a non-calcium ... patients with Chronic Kidney Disease (CKD) on dialysis. ... Pay-Per-View - PR Newswire - HighBeam Research Genzyme Announces Publication of DCOR Study in Kidney International - Aug 30, 2007 The three-year trial involving more than 2100 patients compared the difference in outcomes for patients receiving Renagel® (sevelamer hydrochloride) with ... allamericanpatriots.com Genzyme Announces Positive Results From DCOR Trial Favoring Use of … - Jul 28, 2005 The National Kidney Foundation's 2003 K/DOQI guidelines for Bone Metabolism and Disease in Chronic Kidney Disease recommend sevelamer hydrochloride as a ... RedOrbit Lanthanum Carbonate Did Not Adversely Affect Cognitive Function in … - Feb 9, 2007 At baseline, patients in the standard-therapy group had been receiving calcium acetate (41%), calcium carbonate (33%), sevelamer hydrochloride (20%), ... Medscape Press Release: New In Vitro Data Show That FOSRENOL(R) May Have … - May 5, 2005 New In Vitro Data Show That FOSRENOL(R) May Have Greater Phosphate Binding Affinity Than Sevelamer Hydrochloride. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Press Release: Renagel in New Dialysis Study Published in Kidney … - Jan 8, 2007 Assistance provider for Renagel(R) (sevelamer hydrochloride). Renagel is a non-calcium ... patients with Chronic Kidney Disease (CKD) on dialysis. ... Pay-Per-View - PR Newswire - HighBeam Research … Have Greater Phosphate Binding Affinity than Sevelamer Hydrochlorid... - May 5, 2005 DC, showed that, in vitro, Fosrenol® (lanthanum carbonate) binds phosphate across a broad pH range with higher affinity than sevelamer hydrochloride. ... DG News Genzyme unveils $540m expansion plan for manufacturing, R&D - Sep 27, 2005 Waterford is already the primary tabletting and bottling centre for Renagel (sevelamer hydrochloride), used for patients with chronic kidney disease who are ... In-PharmaTechnologist.com Nabi Biopharmaceuticals Announces Receipt of $2.5 Million Milest - Jun 3, 2008 ...there is no difference in cardiovascular calcification between patients treated with PhosLo and those treated with Renagel (sevelamer hydrochloride). ... Bloomberg Healthcare Costs; American Kidney Fund teams with biotech firm for … - Mar 28, 2005 The National Kidney Foundation's 2003 K/DOQI guidelines for Bone Metabolism and Disease in Chronic Kidney Disease recommend sevelamer hydrochloride as a ... Pay-Per-View - Managed Care Weekly Digest - Factiva, from Dow Jones Renagel Study in New Dialysis Patients Published in Kidney Internation... - Sep 29, 2005 Investigators in the RIND study compared the effects of Renagel(R) (sevelamer hydrochloride) with calcium-based phosphate binders for a period of 18 months ... $4.95 - PR Newswire - ECNext Healthcare Costs; American Kidney Fund teams with biotech firm for … - Mar 29, 2005 The National Kidney Foundation's 2003 K/DOQI guidelines for Bone Metabolism and Disease in Chronic Kidney Disease recommend sevelamer hydrochloride as a ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Fibroblast growth factor 23: the making of a hormone - Nov 1, 2006 ...and including an experimental arm in which phosphate levels were regulated by intermittent dosing of the phosphate binder sevelamer hydrochloride, ... Nature.com Guidelines for disorders of mineral metabolism and secondary … - Jan 13, 2006 ...(2003) Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, ... Nature.com Washington State's Leading Life Sciences Organization Names New … - Nov 18, 2008 Rivera was largely responsible for building the company's US renal division and assisted in the launch of Renagel® (sevelamer hydrochloride) globally. ... International Business Times Mortality effect of coronary calcification and phosphate binder... - Jan 3, 2007 ...were randomized in blocks of 10 and stratified by diabetic status to receive either calcium-containing phosphate binders or sevelamer hydrochloride. ... Nature.com The Dialysis Clinical Outcomes Revisited (DCOR) Study - Jan 7, 2008 ...and compared the difference in outcomes for patients receiving Renagel (sevelamer hydrochloride) with those receiving calcium-based phosphate binders. ... Medscape Study of Tolevamer for C. difficile-Associated Diarrhea Published in ... - Aug 16, 2006 Renagel(R) (sevelamer hydrochloride) controls serum phosphorus in patients with chronic kidney disease on dialysis, and WelChol(R) (colesevelam ... DG News Genzyme invests another EUR 130m in Irish facility - Apr 7, 2008 The first phase was a tableting suite with packaging lines for the manufacture of Renagel (sevelamer hydrochloride), which controls serum phosphorus in CKD. ... In-PharmaTechnologist.com RBT Roundtable: The Renal Diet - Jun 30, 2008 Since the introduction of Renagel (sevelamer hydrochloride) and now with Renvela (sevelamer carbonate), we have focused our efforts on bone and mineral ... Renal Business Today Issues Updates on Genzyme Corp. - Jul 12, 2006 Within the Renal division, revenue for Renagel (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis, ... Free with registration - M2 Presswire - AccessMyLibrary.com Parathyroid Hormone Measurement Useful For Diagnosis Of Renal Bone … - Jun 27, 2008 ...[9] They performed a randomized open-label study comparing the effects on bone histology of sevelamer hydrochloride with those of calcium carbonate at ... Medscape Press Release: Genzyme Files for Approval of Sevelamer Carbonate for ... - Dec 21, 2006 Renvela is being developed as a next generation phosphate binder to replace Renagel(R) (sevelamer hydrochloride), the most-prescribed phosphate binder in ... Pay-Per-View - PR Newswire - HighBeam Research FDA Approves Genzyme's Renvela for Dialysis Patients - Oct 23, 2007 Renvela (sevelamer carbonate) is a next-generation version of Renagel (sevelamer hydrochloride), the most-prescribed phosphate binder in the US, ... FDA news - FDA news (subscription) Genzyme Corporation Reports Strong Growth in Second Quarter 2008 - Jul 24, 2008 Within the Renal business, sales of sevelamer therapies Renagel® (sevelamer hydrochloride) and Renvela grew 16 percent to $168.6 million from $144.9 million ... allamericanpatriots.com Genzyme Reports Financial Results for Fourth Quarter of 2006 and Full... - Feb 14, 2007 Sales of Renagel® (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis, are expected to reach $580-$590 ... webwire.com Genzyme's First-Quarter Sales Below Expectations - Apr 20, 2006 ...temporary shortage of Renagel (sevelamer hydrochloride), Genzyme's phosphate-binding tablet for patients with end-stage renal disease on hemodialysis. ... BioWorld Online - BioWorld Online Renagel in New Dialysis Study Published in Kidney International. - Jan 8, 2007 The National Kidney Foundation's 2003 K/DOQI guidelines for Bone Metabolism and Disease in Chronic Kidney Disease recommend sevelamer hydrochloride as a ... Free with registration - PR Newswire - AccessMyLibrary.com Fresenius Medical Care Announces Positive Results From PhosLo CARE … - Nov 21, 2006 ...there is no difference in cardiovascular calcification between patients treated with PhosLo and those treated with Renagel (sevelamer hydrochloride). ... RedOrbit Fresenius to buy US Renal Care - May 4, 2005 ...a line of vitamin D 2 prohormone products, can be used in tandem with Genzyme's Renagel¿ (sevelamer hydrochloride) and other phosphate binders. ... Medscape Press Release: Apple Announces Time Capsule Wireless Backup for all … - Jan 16, 2008 ...for Renagel capsules (C)1994-98 M2 COMMUNICATIONS LTD ... granted marketing approval for Renagel Capsules (sevelamer hydrochloride) for the reduction . ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: FDA Approves Genzyme's Renvela(TM) for Dialysis … - Oct 22, 2007 Renvela is a next-generation version of Renagel(R) (sevelamer hydrochloride), the most-prescribed phosphate binder in the United States. ... Pay-Per-View - PR Newswire - HighBeam Research Genzyme Reports Financial Results for Fourth Quarter of 2005 and Full... - Feb 15, 2006 Revenue for Renagel® (sevelamer hydrochloride) for patients with end-stage renal disease is expected to reach $495-$505 million this year, compared with ... webwire.com Press Release: Genzyme Corporation Selects Diplomat Specialty … - Jan 17, 2008 Diplomat will be the 2008 national Part D Assistance provider for Renagel(R) (sevelamer hydrochloride). Renagel is a non-calcium/non-metal based phosphorus ... Pay-Per-View - PR Newswire - HighBeam Research The progression of coronary artery calcification in predialysis... - Apr 12, 2007 Gallieni M, Cozzolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder (Letter). ... Nature.com Genzyme Expands its Research and Manufacturing Presence in … - Oct 5, 2005 One of Genzyme's leading products, Renagel® (sevelamer hydrochloride), for patients with end-stage kidney disease, was developed in Waltham, as was WelChol® ... webwire.com Fosrenol Significantly Reduces Tablet Burden for End-Stage Renal … - Apr 21, 2006 Both patients and physicians preferred FOSRENOL (lanthanum carbonate) over sevelamer hydrochloride (HCI) and calcium-based phosphate binders in a ... newswise.com Genzyme Reports Financial Results for Fourth Quarter of 2005 and Full... - Feb 15, 2006 Revenue for Renagel(R) (sevelamer hydrochloride) for patients with end- stage renal disease is expected to reach $495-$505 million this year, compared with ... $4.95 - PR Newswire - ECNext Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude … - Jan 9, 2007 Within the Renal business, Genzyme markets Renagel® (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis, ... webwire.com GENZYME ADVANCES DIARRHEA PRODUCT INTO PIVOTAL TESTING. - Apr 5, 2005 Tolevamer stems from the same technology platform that produced the polymer Renagel (sevelamer hydrochloride), a phosphate binder approved for end-stage ... Pay-Per-View - BIOWORLD Today - Factiva, from Dow Jones Genzyme Receives Approval for Additional Manufacturing at Ireland... - Jul 24, 2006 Waterford is already the primary tableting and bottling center for Renagel(R) (sevelamer hydrochloride). In 2005, the plant produced approximately 3 million ... Free with registration - PR Newswire - AccessMyLibrary.com Genzyme Reports Significant Earnings Growth in Second Quarter - Jul 26, 2007 Renvela is a second-generation, buffered form of Renagel® (sevelamer hydrochloride) that will enable Genzyme to expand the market for its phosphate binder ... webwire.com PRESS RELEASE: Hyperion Therapeutics Announces Senior … - Oct 4, 2007 Rivera was largely responsible for building the company's US renal business and assisted in the launch of Renagel® (sevelamer hydrochloride) globally. ... FierceBiotech Fosrenol Has Long-Term Safety and Efficacy in End-Stage Renal Disease... - Nov 14, 2005 Data presented at the ASN meeting showed that the phosphate-binding affinity of Fosrenol® was more than 200 times higher compared to sevelamer hydrochloride ... DG News Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue - Jan 9, 2006 Fourth-quarter revenue for Renagel® (sevelamer hydrochloride), a phosphate binder for patients with end-stage kidney disease on hemodialysis, ... webwire.com Lanthanum Appears Useful, Safe for Long-Term Treatment of … - Nov 15, 2005 Another non-calcium containing phosphate-binding agent, which was approved in 1998, is sevelamer hydrochloride ( Renagel). An advantage that lanthanum ... Medscape Forsenol reduces tablet burden on end stage renal disease patients... - Apr 26, 2006 Both patients and physicians preferred FOSRENOL (lanthanum carbonate) over sevelamer hydrochloride (HCI) and calcium-based phosphate binders in a ... News-Medical.net Renagel in New Dialysis Study Published in Kidney International - Jan 15, 2007 The US-based National Kidney Foundation's 2003 K/DOQI guidelines for Bone Metabolism and Disease in Chronic Kidney Disease recommend sevelamer hydrochloride ... DG News Genzyme Reports Second-Quarter GAAP EPS of $0.46, Non-GAAP EPS … - Jul 14, 2005 ...improved margins for both Renagel(R) (sevelamer hydrochloride) and for enzyme replacement products resulting from increased utilization of manufacturing ... $4.95 - PR Newswire - ECNext NEW DATA BACKS FOSRENOL AS TREATMENT CHOICE FOR END- … - Nov 15, 2005 ASN meeting showed that the phosphate-binding affinity of FOSRENOL(R) was more than 200 times higher compared to sevelamer hydrochloride (HCl) at pH 3. ... Free with registration - AsiaPulse News - AccessMyLibrary.com Event Brief of Q3 2006 Genzyme Corporation Earnings Conference Call -... - Oct 1, 2006 But Renagel, sevelamer hydrochloride, was not designed for the pre-dialysis market, and that's why sevelamer carbonate had to be developed in order to give ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Genzyme given green light to make kidney drug at Irish plant - Aug 14, 2006 Waterford is already the primary tabletting and bottling centre for Renagel (sevelamer hydrochloride) - a drug used in patients with chronic kidney disease ... In-PharmaTechnologist.com Higher Initial Doses of FOSRENOL Result in More Rapid Control of Mean... - Apr 23, 2006 Both patients and physicians preferred FOSRENOL (lanthanum carbonate) over sevelamer hydrochloride (HCI) and calcium-based phosphate binders in a ... RxPG NEWS Abstract and Introduction - Jul 9, 2007 ...calcium–based phosphate binders, sevelamer hydrochloride and aluminum binders, corresponding to two periods according to the introduction of cinacalcet. ... Medscape Hyperphosphatemia and Mortality: What's The Connection - Dec 20, 2005 ...from the gut include aluminum hydroxide, calcium carbonate, calcium acetate, magnesium carbonate, sevelamer hydrochloride, and lanthanum carbonate. ... Medscape Event Brief of Q4 2005 Genzyme Corporation Earnings Conference Call -... - Feb 15, 2006 ...which is the basis for our regulatory filing for our current label, basically that it that takes on the same label as sevelamer hydrochloride. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Amgen's Ilypsa Buy: $420M Gets Phase II CKD Therapy - Jun 6, 2007 ...s Renagel (sevelamer hydrochloride), cleared by the FDA in 1998 for patients with end-stage renal disease on hemodialysis. (See BioWorld Today, April 28, ... BioWorld Online - BioWorld Online Biotech majors face output woes - Apr 11, 2005 Genzyme also faces increased competition for Renagel (sevelamer hydrochloride), its leading brand outside of its genetic disorder franchise, ... ICIS Fosrenol's Threat To Renagel May Be Leveling Off: Report - Apr 18, 2005 While the news about tolevamer proved worthy of headlines, Renagel (sevelamer hydrochloride) has been more a focus of interest lately, as the competition ... BioWorld Online - BioWorld Online BizTimes Daily for Thursday, June 30, 2005 - BizTimes - Jun 30, 2005 ...will begin selling two complementary products to nephrologists in the United States: Hectorol (doxercalciferol) and Renagel (sevelamer hydrochloride). ... Milwaukee Small Business Times Lanthanum Carbonate Improves Serum P Control in Most CKD Stage 5 … - Dec 14, 2006 The most common binders were calcium carbonate (60%) and sevelamer hydrochloride (56%); 11% of patients were taking aluminum-based binders as part of ... Medscape Press Release: Decreased Hospitalizations and Health Care Costs … - Nov 16, 2006 16 /PRNewswire-FirstCall/ -- Genzyme Corp. announced today that patients using Renagel(R) (sevelamer hydrochloride) experienced lower rates of ... Pay-Per-View - PR Newswire - HighBeam Research sevelamer carbonate Genzyme submitted for approval, USA (kidney … - Jan 8, 2007 ...nonabsorbed phosphate-binding polymer hydrogel, to replace sevelamer hydrochloride (RENAGEL), for the treatment of hyperphosphatemia in patients with ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Press Release: Genzyme Announces Successful Completion of Study … - Apr 16, 2007 The drug was well tolerated with a safety profile consistent with the clinical experience of patients on dialysis using Renagel(R) (sevelamer hydrochloride) ... Pay-Per-View - PR Newswire - HighBeam Research Genzyme Delivers Strong Third-Quarter Results. - Oct 18, 2005 Within the Renal area, revenue for Renagel(R) (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis, ... $4.95 - PR Newswire - ECNext Genzyme Delivers Excellent Fourth-Quarter and 2004 Performance ------... - Feb 17, 2005 Within the Renal area, revenue for Renagel(R) (sevelamer hydrochloride) is expected to rise to $420-$430 million, compared with $363.7 million in 2004. ... $4.95 - PR Newswire - ECNext Genzyme, Bone Care International Announce Shareholder Approval of … - Jun 30, 2005 ...begin selling two complementary products to nephrologists in the United States: Hectorol(R) (doxercalciferol) and Renagel(R) (sevelamer hydrochloride). ... $4.95 - PR Newswire - ECNext Genzyme Expands Global Infrastructure for Manufacturing, R&D. - Sep 22, 2005 In addition, Genzyme's Haverhill, UK plant, which was significantly expanded in recent years to produce bulk sevelamer hydrochloride for Renagel, ... $4.95 - PR Newswire - ECNext Maxxon increases suite of safety products and other healthcare news -... - Jul 29, 2005 ...in mortality and morbidity outcomes for Renagel(R) (sevelamer hydrochloride) patients, compared to patients who used calcium-based phosphate binders. ... $4.95 - M2 Presswire - ECNext Genzyme Reports Significant Revenue and Earnings Growth in First … - Apr 25, 2007 Within the Renal business, sales of Renagel(R) (sevelamer hydrochloride) grew 16 percent to $137.4 million, up from $118.7 million in the first quarter a ... $4.95 - PR Newswire - ECNext Genzyme Reports Strong Third-Quarter Financial Results. - Oct 12, 2006 Within the Renal business, Genzyme markets Renagel(R) (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on ... $4.95 - PR Newswire - ECNext æ´—è…Žç—…æ‚£æ»äº¡çŽ‡é™?34% - May 10, 2006 ...å‰?美國腎臟醫å¸æœƒç?†äº‹é•·ã€?Baylor大å¸è‡¨åºŠæ•™æŽˆWadi Suki指出，新一代磷çµ?å?ˆåŠ‘sevelamer hydrochloride，是一種å?«èƒºè?šå?ˆç‰©ï¼Œå®ƒå?¯æ??供大é‡?æ£é›»è?·ï¼Œèˆ‡å¸¶è² é›»è?·çš„磷酸鹽 ... è?¯å?ˆæ–°è?žç¶² Press Release: Genzyme Reports First-Quarter GAAP EPS of $0.36, Non- … - Apr 21, 2005 Renagel(R) (sevelamer hydrochloride) and for enzyme replacement products resulting from increased utilization of the company's manufacturing facilities. ... Pay-Per-View - PR Newswire - HighBeam Research Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosi... - Jan 30, 2006 ...such as calcium carbonate (or calcium acetate), ammonium-based compounds, and phosphate-binding polymers (Renagel; sevelamer hydrochloride, Grnzyme). ... Pay-Per-View - Pharma Japan - Factiva, from Dow Jones Press Release: Shire Demonstrates Commitment to Improving Patient … - Jun 25, 2007 PR Newswire Europe; April 21, 2006 ; 700+ words ... ... and physicians preferred FOSRENOL(r) (lanthanum carbonate) over sevelamer hydrochloride (HCI) and ... Pay-Per-View - PR Newswire Europe - HighBeam Research Genzyme Reports Strong Fourth-Quarter Revenue Growth. - Jan 11, 2005 Within the Renal area, fourth-quarter revenue for Renagel(R) (sevelamer hydrochloride) grew 22 percent to $99 million, up from $82 million in the fourth ... $4.95 - PR Newswire - ECNext Shire finds in vitro efficacy for Fosrenol.(Brief Article) - May 23, 2005 Fosrenol (lanthanum carbonate) binds phosphate across a broad pH range with higher affinity than the common phosphorius trap, sevelamer hydrochloride. ... $4.95 - Pharma Marketletter - ECNext Press Release: FOSRENOL(r) Significantly Reduces Tablet Burden for … - Apr 21, 2006 Both patients and physicians preferred FOSRENOL(r) (lanthanum carbonate) over sevelamer hydrochloride (HCI) and calcium-based phosphate binders in a ... Pay-Per-View - PR Newswire Europe - HighBeam Research calcium acetate Nabi provides update on development.(Brief Article) - Mar 28, 2005 ...arterial calcification in around 150 endstage renal disease patients treated with PhosLo and sevelamer hydrochloride are to be reported in the second half ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Press Release: Genzyme Announces Positive Results from DCOR Trial … - Jul 28, 2005 ...in mortality and morbidity outcomes for patients receiving Renagel(R) (sevelamer hydrochloride) with those using calcium-based phosphate binders. ... Pay-Per-View - PR Newswire - HighBeam Research Packing an unusual punch: treatments show promise for pityriasis... - Feb 1, 2007 Therefore, she says researchers have begun looking into nonaluminum phosphate binders such as Renagel (sevelamer hydrochloride, Genzyme). ... $4.95 - Dermatology Times - ECNext Article: Genzyme reports DCOR trial using Renagel in dialysis... - Aug 15, 2005 ...in mortality and morbidity outcomes for patients receiving Renagel (sevelamer hydrochloride) with those using calcium-based phosphate binders. ... Pay-Per-View - Transplant News - HighBeam Research Genzyme Corporation; Renagel study in new dialysis patients shows … - Oct 26, 2005 Investigators in the RIND study compared the effects of Renagel (sevelamer hydrochloride) with calcium-based phosphate binders for a period of 18 months in ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Press Release: Genzyme, Bone Care International Announce … - Jun 30, 2005 ...begin selling two complementary products to nephrologists in the United States: Hectorol(R) (doxercalciferol) and Renagel(R) (sevelamer hydrochloride). ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Genzyme Announces Positive Results from Trial and US … - Jul 28, 2005 ...in mortality and morbidity outcomes for patients receiving Renagel (sevelamer hydrochloride) with those using calcium-based phosphate binders. ... Pay-Per-View - M2 Presswire - HighBeam Research Renal Failure; Renagel study in new dialysis patients shows positive ... - Oct 24, 2005 Investigators in the RIND study compared the effects of Renagel (sevelamer hydrochloride) with calcium-based phosphate binders for a period of 18 months in ... Pay-Per-View - Pharma Business Week - Factiva, from Dow Jones Press Release: Maxxon increases suite of safety products and other … - Jul 29, 2005 ...in mortality and morbidity outcomes for Renagel(R) (sevelamer hydrochloride) patients, compared to patients who used calcium-based phosphate binders. ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: New Six-year Data Supports FOSRENOL(R) as a … - Nov 12, 2005 ASN meeting showed that the phosphate-binding affinity of FOSRENOL(R) was more than 200 times higher compared to sevelamer hydrochloride (HCl) at pH 3. ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Genzyme Receives Approval for Additional Manufacturing... - Jul 24, 2006 Waterford is already the primary tableting and bottling center for Renagel(R) (sevelamer hydrochloride). In 2005, the plant produced approximately 3 million ... Pay-Per-View - PR Newswire - HighBeam Research Renal Failure; Renagel study in new dialysis patients shows positive ... - Oct 30, 2005 Investigators in the RIND study compared the effects of Renagel (sevelamer hydrochloride) with calcium-based phosphate binders for a period of 18 months in ... Pay-Per-View - Heart Disease Weekly - Factiva, from Dow Jones |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |